1 Min Read
May 2 (Reuters) - Yungjin Pharm Co Ltd:
* announced it has entered into global licensing agreement on Yungjin Pharm's compound KL1333 for genetic mitochondrial disorders
* will now initiate activities in preparation for next clinical study in Europe and/or in U.S.
* NeuroVive will pay Yungjin Pharm upfront payments of $1 million at signing
* NeuroVive will pay Yungjin Pharm additional $1 million after completion of a successful phase I clinical trial Source text for Eikon: Further company coverage: